Metsera, Inc.
MTSR
Rang in aandelen
#2568
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Aandeelprijs
$70.50
Laatst gesynchroniseerd: 2025-11-14
Marktkapitalisatie
$7.33B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
33.60%
Land
US
Handel Metsera, Inc. (MTSR)
Categorie
Healthcare
Koersgeschiedenis voor Metsera, Inc. (MTSR)
Hoogste slotkoers: $72.34 op 2025-11-01
Laagste slotkoers: $26.50 op 2025-01-01
Laagste slotkoers: $26.50 op 2025-01-01
Koersgeschiedenis van Metsera, Inc. van 2025 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -10.54% |
| 2025 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $533.13 | 25.02% |
US
|
|
| $235.39 | 776.69% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $889.46 | 9.25% |
NL
|
|
| $289.74 | 1.80% |
BE
|
